Aprea Therapeutics Inc (APRE) Stock Price, Quote & News

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid t...

Industry: Biotechnology

Sector: Healthcare

Phone: 215 948 4119

Website: aprea.com

Address:

3805 Old Easton Road, Doylestown, United States

cloudhedge May. 13 at 3:43 PM

Is $APRE moving toward the next phase of a biotech breakout? Oppenheimer has initiated an Outperform rating with a $5 price target. Analysts point to a valuation discount, while Aprea’s WEE1 inhibitor program continues to gain increasing institutional attention and traction. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!

0 · Reply

Bulltrader988 May. 13 at 10:33 AM

$APRE 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-reports-first-quarter-2026-financial-results-and-34l1uxshvz6p.html

0 · Reply

JSP_Dilution_Player May. 11 at 3:24 PM

$IMMP $APRE $INAB at ASCO as well. NO POSITION... just watching for now

0 · Reply

AtomV May. 11 at 10:13 AM

$APRE waiting for a pump before the reverse split.😃

0 · Reply

Bulltrader988 May. 10 at 7:09 PM

$APRE .... 👃👀 https://x.com/i/status/2052407226862596569

0 · Reply

Bulltrader988 May. 10 at 7:09 PM

$APRE PT $ 5 👃👀 https://x.com/i/status/2052799398229545466

0 · Reply

InvestingSpaceman May. 8 at 8:40 PM

$RDGT $APRE $DGNX $MSGY TU

0 · Reply

Nanu108 May. 7 at 8:27 PM

$APRE I'm in 113,000 shares this week

0 · Reply

notreload_ai May. 7 at 3:16 PM

Oppenheimer backs $APRE with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential. https://notreload.xyz/xy/why-oppenheimer-is-bullish-on-tiny-biotech-aprea-therapeutics/

0 · Reply

SuperGreenToday May. 5 at 1:53 AM

$APRE

0 · Reply

Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year

May 13, 2026, 6:30 AM EDT - 8 hours ago

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

2026-05-07T11:31:05.000Z - 6 days ago

Aprea Therapeutics initiated with an Outperform at Oppenheimer

2026-04-22T21:06:33.000Z - 20 days ago

Aprea Therapeutics files to sell 74.35M shares of common stock for holders

Apr 21, 2026, 10:15 AM EDT - 22 days ago

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Apr 1, 2026, 8:30 AM EDT - 6 weeks ago

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

2026-03-31T10:18:45.000Z - 6 weeks ago

Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright

2026-03-30T12:44:02.000Z - 6 weeks ago

Aprea Therapeutics confirms partial response in ongoing ACESOT-1051 trial

Mar 30, 2026, 8:01 AM EDT - 6 weeks ago

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Mar 30, 2026, 8:00 AM EDT - 6 weeks ago

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

2026-03-16T12:06:55.000Z - 2 months ago

Aprea Therapeutics reports Q4 EPS (32c) vs. (49c) last year

2026-03-16T12:05:48.000Z - 2 months ago

Aprea Therapeutics sees cash runway into 1Q27

Mar 16, 2026, 8:00 AM EDT - 2 months ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Feb 26, 2026, 8:40 AM EST - 2 months ago

Aprea Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-20T11:11:20.000Z - 2 months ago

Aprea Therapeutics files to sell 12.58M shares of common stock for holders

2026-02-18T13:17:13.000Z - 3 months ago

Aprea Therapeutics announces additional clinical activity for APR-1051

Feb 18, 2026, 8:00 AM EST - 3 months ago

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Feb 17, 2026, 8:00 AM EST - 3 months ago

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-12T13:43:38.000Z - 3 months ago

Aprea announces expansions of its global intellectual property estate

Feb 12, 2026, 8:30 AM EST - 3 months ago

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

2026-02-10T13:20:30.000Z - 3 months ago

Aprea Therapeutics price target lowered to $7 from $11 at Wedbush

2026-02-04T13:35:12.000Z - 3 months ago

Aprea Therapeutics appoints Kennedy as Chief Medical Advisor

Feb 4, 2026, 8:30 AM EST - 3 months ago

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

2026-01-29T17:30:16.000Z - 3 months ago

Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright

2026-01-29T13:37:09.000Z - 3 months ago

Aprea Therapeutics prices 6.29M shares at 89c in private placement

2026-01-29T13:36:47.000Z - 3 months ago

Aprea Therapeutics announces early PoC data in ACESOT-1051 trial

Jan 29, 2026, 8:27 AM EST - 3 months ago

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Jan 29, 2026, 8:25 AM EST - 3 months ago

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2025-12-19T21:20:46.000Z - 5 months ago

Aprea Therapeutics files to sell 5.5M shares of common stock for holders

2025-12-18T16:35:27.000Z - 5 months ago

Aprea Therapeutics price target lowered to $5 from $20 at H.C. Wainwright

2025-12-18T13:41:52.000Z - 5 months ago

Aprea Therapeutics CEO issues letter to shareholders

Dec 18, 2025, 8:30 AM EST - 5 months ago

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

2025-12-09T13:46:23.000Z - 5 months ago

Aprea Therapeutics prices 2.62M shares at $1.165 in private placement

Dec 9, 2025, 8:30 AM EST - 5 months ago

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Nov 12, 2025, 8:30 AM EST - 6 months ago

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Oct 24, 2025, 8:30 AM EDT - 7 months ago

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Oct 15, 2025, 8:00 AM EDT - 7 months ago

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Sep 9, 2025, 3:30 PM EDT - 8 months ago

Aprea Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:30 AM EDT - 9 months ago

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Jun 25, 2025, 9:00 AM EDT - 11 months ago

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

May 14, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Feb 5, 2025, 8:00 AM EST - 1 year ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Dec 11, 2024, 8:30 AM EST - 1 year ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Sep 9, 2024, 5:15 PM EDT - 1 year ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 24, 2024, 9:00 AM EDT - 2 years ago

Aprea Therapeutics Transcript: Study Update

Jun 21, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Jun 17, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

May 28, 2024, 8:45 AM EDT - 2 years ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 14, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:01 PM EDT - 2 years ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

May 2, 2024, 9:15 AM EDT - 2 years ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Apr 10, 2024, 12:00 PM EDT - 2 years ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Mar 26, 2024, 7:45 AM EDT - 2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 7:48 AM EDT - 2 years ago

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Mar 11, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Mar 11, 2024, 8:29 AM EDT - 2 years ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Mar 5, 2024, 4:45 PM EST - 2 years ago

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Feb 6, 2024, 8:01 AM EST - 2 years ago

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Jan 30, 2024, 8:00 AM EST - 2 years ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Nov 9, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

cloudhedge May. 13 at 3:43 PM

0 · Reply

Bulltrader988 May. 13 at 10:33 AM

$APRE 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-reports-first-quarter-2026-financial-results-and-34l1uxshvz6p.html

0 · Reply

JSP_Dilution_Player May. 11 at 3:24 PM

$IMMP $APRE $INAB at ASCO as well. NO POSITION... just watching for now

0 · Reply

AtomV May. 11 at 10:13 AM

$APRE waiting for a pump before the reverse split.😃

0 · Reply

Bulltrader988 May. 10 at 7:09 PM

$APRE .... 👃👀 https://x.com/i/status/2052407226862596569

0 · Reply

Bulltrader988 May. 10 at 7:09 PM

$APRE PT $ 5 👃👀 https://x.com/i/status/2052799398229545466

0 · Reply

InvestingSpaceman May. 8 at 8:40 PM

$RDGT $APRE $DGNX $MSGY TU

0 · Reply

Nanu108 May. 7 at 8:27 PM

$APRE I'm in 113,000 shares this week

0 · Reply

notreload_ai May. 7 at 3:16 PM

0 · Reply

SuperGreenToday May. 5 at 1:53 AM

$APRE

0 · Reply

Bulltrader988 May. 3 at 8:34 PM

$APRE "...Presentation: Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)... Poster Session - Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology... May 30, 2026, 1:30 PM-4:30 PM CDT..." 👃👀 https://www.crweworld.com/article/news-provided-by-globenewswire/3826293/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting

0 · Reply

Bulltrader988 Apr. 28 at 11:49 AM

$APRE 👃👀 https://www.stocktitan.net/news/APRE/catal-ym-appoints-christian-s-schade-as-chairman-of-the-board-of-p91o3q7xlluw.html

0 · Reply

Bulltrader988 Apr. 27 at 8:45 PM

$APRE 13 G/ filled today ah: Orin Hirschman owns 1,186,294 shares= 9.9 % ownership 👃👀 https://www.sec.gov/Archives/edgar/data/1131362/000149315226019073/xslSCHEDULE_13G_X02/primary_doc.xml

0 · Reply

Bulltrader988 Apr. 21 at 4:37 PM

$APRE "....today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago..." 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-0athjb0e4g94.html

0 · Reply